Endocrine treatment of breast cancer.
Ravdin
P M
PM
Division of Medicine Oncology, University of Texas Medical School at San Antonio.
D000728:Androgens / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000628:therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D010052:Ovariectomy / Q000009:adverse effects; D017698:Postmenopause; D017697:Premenopause; D011372:Progestins / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use
D000728:Androgens; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D004967:Estrogens; D011372:Progestins; D013629:Tamoxifen; D017273:Goserelin